Kornimate/medical-research-clean huggingface dataset:
study of a cohort of cases of synovial sarcoma treated in the orthopedic surgery and traumatology department of the hospital de sant pau between 1983 and 2016

Conditions: Soft Tissue Sarcoma Adult

Summary: the main objectives of this study are the following: to describe the prognostic factors of survival of synovial sarcoma in patients treated by the orthopedic surgery unit oncologic of the orthopedic surgery and traumatology service of the hospital de sant pau during the years 1983-2016.

another objectives of this study are: to analyze exhaustively a series of cases of synovial sarcoma (as an example of classic subtype of soft tissue sarcoma) to analyse the complementary tests performed and their evolution over time. to analyse the results of surgical treatment and adjuvant therapies in synovial sarcoma and its evolution over time. to study the prognostic factors dependent on the patient and the applied therapeutics. to establish a results-based treatment and follow-up algorithm for patients diagnosed with synovial sarcoma. to describe the epidemiological characteristics of the group of patients in the study. to evaluate the overall survival and disease-free survival as well as the mortality of the disease. to assess the rate of local recurrence and remote dissemination of synovial sarcomas in the series. to demonstrate the influence of neoadjuvant chemotherapy and radiotherapy in the treatment of the tumor. conduct a study by age group with respect to the influence on patient survival. to carry out a study by tumor-sized groups with respect to the influence on the survival of the patients. to carry out a chronological study on the influence of the advances in the treatments on the survival of the patients. compare the results obtained with the published literature.

Eligibility criteria:
inclusion criteria: the inclusion criteria were: diagnosed cases of synovial sarcoma by the service of pathological anatomy and treated by unit orthopedic surgery oncology, in location of limbs, paravertebral trunk and/or pelvis. we studied the complete medical history of the cases available for the analysis and with a minimum follow-up of 12 months. exclusion criteria:

Keywords: synovial sarcoma
a better everyday life among persons with chronic conditions

Conditions: Chronic Conditions, Multiple

Summary: background: persons living with chronic conditions often have decreased ability to perform activities of daily living (adl) tasks, stressing a need to develop and evaluate intervention programs addressing decreased adl ability. guided by the british medical research council's guidance (mrc) on how to develop and evaluate complex interventions, the program "a better everyday life" (able), a home-based intervention program, was developed and feasibility tested. the current phase concerns a full-scale evaluation of the able program including evaluation of effectiveness, processes and cost-effectiveness. material and methods: the design involves a randomized controlled trial, initiated with an internal pilot. the study will include eighty (n=80) home dwelling persons living with chronic conditions, experiencing problems performing adl. participants are randomized to either intervention (able) or control (usual care). co-primary outcomes are self-reported adl ability measured using adl-questionnaire (adl-q) and observed adl motor ability measured using assessment of motor and process skills (amps). secondary outcomes are perceived satisfaction with adl task performance measured using adl-q; observed adl process ability measured using amps; and goal attainment measured using goal-attainment-scaling (gas). data is collected at baseline, post intervention and six months after baseline. process evaluation data are collected using registration forms and semi-structured qualitative interviews. the economic evaluation will be performed from a health care sector perspective with 6 months follow-up. costs will be estimated based on micro costing and national registries. effects will be quality adjusted life years and changes in amps adl ability.

due to the covid-19 pandemic, the study was truncated on march 11th 2020. data collected at this time was assessed to be sufficient to answer most pilot study questions, and it was decided to turn the internal pilot into an external pilot. based on the results of the external pilot, a few adjustments on outcome measurements, inclusion criteria and extraction of information on usual care were applied, before initiation of the full scale trial. hence adl-i replaced adl-q as primary outcome measurement. data collection for full scale trial was initiated august 1st 2020.

Eligibility criteria:
inclusion criteria: * ≥ one year since medical diagnosed with one or more chronic conditions * perceive problems performing adl tasks * ≥ 18 years of age * lives in own home * motivated and ready for making changes in adl performance * motivated and ready to participate in program * communicates independently and relevant * able to understand and relevantly answer a questionnaire exclusion criteria: * padl problems with acute need for help (if the client does not already receive help from home carer * known substance abuse * mental illness, and/or other acute illness effecting adl task performance * communication barriers (e.g. severe cognitive deficits; and barriers that prevents receiving information on study)
effect of an immunotoxin on activated human macrophages in those with allergic rhinitis or mild intermittent asthma

Conditions: Atopy; Rhinitis; Bronchial Asthma

Summary: the primary objective of this study is to isolate macrophages by using bronchoalveolar lavage (bal) for different in vitro experiments. therefore, following a baseline bal, allergen, endotoxin, and saline will be instilled into three different lung segments during the first bronchoscopy. after 24 hours during a second bronchoscopy, bal fluid will be collected in these challenged segments to harvest invaded cells for in vitro experimentation. in addition, segmental bronchial biopsies will be taken to assess the degree of local inflammation.


Eligibility criteria:
inclusion criteria: * physician diagnosis of atopy (allergic rhinitis or mild intermittent asthma) * age 18-55 years * nonsmoker (\> 5 years) * forced expiratory volume in 1 second (fev1) \> 70% of the predicted value * a positive skin prick test for grass mix or d. pteronyssinus at or within 12 months prior to the screening visit * informed consent * females with negative pregnancy test exclusion criteria: * infections of the respiratory tract within the last month * past or present disease, which as judged by the investigator, may affect the outcome of this study. these diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis). * pathological findings in blood tests (differential blood count, blood clotting, electrolytes, liver enzymes, retention parameters) * subject is undergoing allergen desensitization therapy * permanent medication * systemic or inhaled corticosteroid use within the last month * anti-inflammatory medication within the last month * pregnancy * neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol assignment * there is a risk of non-compliance with study procedures * participation in a clinical trial 30 days prior to enrolment

Keywords: allergic rhinitis
rct of pain perception with fast and slow tenaculum application

Conditions: Pain, Acute; Pain, Procedural

Summary: this project will be a randomized controlled trial (rct) measuring pain perception with two different tenaculum placement techniques on the uterine cervix. a tenaculum is an instrument used to hold the cervix (the opening to the uterus or womb) in place. the trial will measure pain perception with a visual analog scale (vas) from 0 to 100 mm for two different tenaculum placement techniques, fast and slow closure on the uterine cervix. the main objective of this study is to determine if there is a difference in pain perception with fast compared to slow tenaculum placement techniques on the uterine cervix. we hypothesize that the slow technique will be perceived as less painful for subjects as measured on a 0 mm to 100 mm visual analog scale (vas). subsidiary objectives include describing overall pain levels during the procedure.

in order to detect a 15 mm difference on the vas with two-sided 5% alpha and 80% power and a standard deviation of 33 mm (based on prior studies), a total of 71 subjects per group are required. we aim to recruit 75 subjects per arm in order to account for possible drop out.

Eligibility criteria:
inclusion criteria: 1. plans for iud insertion or endometrial biopsy; 2. 18 to 49 years of age; 3. not taken analgesics or anxiolytics in the previous 24 hours; 4. the ability and are willing to give informed consent. exclusion criteria: 1. do not speak english unless interpreter present; 2. taken any narcotic or opiate medication in the last 24 hours. 3. taken any recreational or illegal drugs in the last 24 hours, such as marijuana, heroin, cocaine, crack, or methamphetamines. 4. taken any anti-anxiety medication or drug in the last 24 hours. 5. taken any nsaids or tylenol in the last 12 hours.
study of anlotinib hydrochloride capsule combined with chemotherapy in subjects with squamous non-small cell lung cancer

Conditions: Squamous Non-small Cell Lung Cancer

Summary: anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as vegfr1/2/3, fgfr1/2/3, and other tumor-associated kinases involved in cell proliferation such as pdgfrα/β, c-kit, and ret have significant inhibitory activities.


Eligibility criteria:
inclusion criteria: 1. squamous non-small cell lung cancer. 2. a measurable lesion. 3. the disease progression occurs \>12 months after the end of the last treatment. 4.18-75 years old ; eastern cooperative oncology group (ecog) performance status of 0 to 1; life expectancy ≥ 3 months. 5.adequate laboratory indicators. 6.no pregnant or breastfeeding women, and a negative pregnancy test. 7.understood and signed an informed consent form. exclusion criteria: 1. the tumor invades the large blood vessels. 2. central type squamous non-small cell lung cancer. 3. egfr/alk gene mutation is positive. 4. has used egfr inhibitors and alk inhibitors. 5. has other malignant tumors within 5 years. 6. has a variety of factors affecting oral medications. 7. symptomatic brain metastasis. 8. uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage. 9. spinal cord compression. 10. has received radiotherapy, chemotherapy, surgery less than 4 weeks before randomization. 11. severe allergies to therapeutic medications. 12. adverse events caused by previous treatment did not recover to grade 1. 13. has received major surgical treatment within 4 weeks before randomization. 14. arteriovenous thrombosis occurred within 6 months. 15. has drug abuse history that unable to abstain from or mental disorders. 16. has severe or uncontrolled disease. 17. participated in other clinical trials within 4 weeks. 18. according to the investigators' judgement.
dabigatran etexilate for stroke prevention in patients with atrial fibrillation and mild to moderate renal impairment

Conditions: Atrial Fibrillation

Summary: non-interventional, observational study of physicians' use of dabigatran etexilate for stroke prevention in patients with atrial fibrillation and mild to moderate renal impairment


Eligibility criteria:
inclusion criteria: * patients with atrial fibrillation foreseen for pradaxa anticoagulation according to physician's decision for stroke prevention * patients with mild or moderate renal impairment * age \>= 18 years at enrollment exclusion criteria: - severe renal impairment (creatinine clearance \< 30 ml/min)
exercise and inflammation

Conditions: Cardiovascular Disease

Summary: the purpose of this study is to test the hypothesis that aerobic exercise leads to attenuation of the inflammatory response to lipopolysaccharide (lps) stimulation.

aerobic exercise - the most widely recommended health behavior - is recognized to reduce the risk of coronary heart disease, so much so that consensus panels routinely include it as part of a cardioprotective regimen for healthy people, but the physiological or mechanistic basis of this protection is uncertain. understanding the mechanisms has considerable public health significance because it will allow development and testing of targeted interventions to produce comparable cardioprotective effects more directly or in cases where aerobic exercise is not possible. this application proposes to test the hypothesis that aerobic training leads to attenuation of the inflammatory response to lps stimulation and to examine the role played by exercise-induced increases in vagal activity, improvements in mood, and decreased expression of toll receptor 4 (tlr4), the cognate receptor for endotoxin expressed by monocytes.

Eligibility criteria:
inclusion criteria: 1. age 20-45 years old 2. english-speaking 3. ambulatory 4. bmi \< 32 5. pre-menopausal (women only) with regular cycle lengths between 26-32 days 6. "average" fitness as determined by american heart association standards (vo2max \< 43 ml/kg/min for men, \< 37 ml/kg/min for women) vo2max test exclusion criteria: 1. use of anti-psychotic medications 2. current of past major depressive disorder, or total symptom score \> 10 3. bmi\<18 4. heart disease 5. hypertension 6. diabetes mellitus 7. neurologic disease 8. smoking 9. individuals with ischemic heart disease, cardiac arrhythmias, peripheral vascular disease, orthopedic problems such as foot, leg, hip and spine problems,movement disorders, other neurological disorders affecting gait or balance, conditions or treatments associated with impaired thermoregulation, or other medical problems, for which aerobic training would be contraindicated. 10. use of any medication with autonomic effects 11. use of birth control medication 12. ischemic changes, abnormal blood pressure responses, significant ectopy 13. appears to be at high risk to be unable to adhere to study protocol
68ga-nota-rm26 pet/ct in prostate cancer patients

Conditions: Prostate Cancer

Summary: this is an open-label positron emission tomography/computed tomography (pet/ct) study to investigate the diagnostic performance and evaluation efficacy of 68ga-nota-rm26 in prostate cancer patients. a single dose of 111-148 mega-becquerel (mbq) 68ga-nota-rm26 will be injected intravenously. visual and semiquantitative method will be used to assess the pet/ct images.

the gastrin-releasing peptide receptor (grpr), also known as bombesin receptor subtype ii (bb2), is a member of the g protein-coupled receptor family of bombesin receptors. grpr is over-expressed in various types of human tumors including prostate cancer. rm26, a grpr antagonist with high affinity, was discovered by peptide backbone modification of bombesin analogues.to target gastrin-releasing peptide receptor in neoplastic cells of human prostate cancer, peptide nota-rm26 was synthesized with a peg3 linker between nota and rm26, and then labeled with 68ga. an open-label whole-body pet/ ct study was designed to investigate the safety and dosimetry of 68ga-nota-rm26 and to assess its clinical diagnostic value in patients with prostate cancer.

Eligibility criteria:
inclusion criteria: * patients with diagnosis of primary prostate cancer having a prostate neoplasm identified by ultrasound or mri, being diagnosed by needle biopsy as having prostate cancer, having undergone whole-body bone scanning, and being able to provide basic information and sign the written informed consent form. exclusion criteria: * the exclusion criteria included claustrophobia, kidney or liver failure, and inability to fulfill the study.
evaluation of noninvasive vagus nerve stimulation on functional status in ischemic stroke

Conditions: Stroke, Ischemic; Hemiplegia; Hemiparesis;Poststroke/CVA

Summary: in this study, the effectiveness of vagus nerve stimulation in patients with right and left hemiparesis will be compared with each other and with the sham application.

this prospective study will include 80 participants with a diagnosis of ischemic stroke who meet the inclusion criteria. in addition to the conventional rehabilitation program, non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the vagustim™-ear tens electrode. as a vagus stimulation protocol, 10 sessions, 30 minutes, noninvasive auricular stimulation will be applied, stimulation frequency is 10 hz, the pulse width is 300 µs, biphasic. in the study, sham vagus nerve stimulation (0 ma) will be applied to the participants in the control group. the study will be completed when the evaluation of the participants is made in the 1st and 3rd months after the last intervention. the upper extremity functions of the patients participating in the study were determined by fugl-meyer upper extremity test and box and block test, upper and lower extremity spasticities by modified ashworth scale, and sleep quality by pittsburgh sleep quality index. quality of life will be evaluated with the stroke-specific quality of life scale, balance functions with the berg balance test, dependency levels in daily activities with the barthel index, and sympathetic dysfunctions with compass-31. participants' blood pressure and pulse values will be evaluated before and after each session.

Eligibility criteria:
inclusion criteria: * history of subacute-chronic ischemic stroke (3-12 months) exclusion criteria: * bilateral or unilateral previous injury to the vagus nerve (eg injury during carotid endarterectomy). * severe depression (beck depression scale \> 29) * current use of any other stimulation device, such as a pacemaker or other neurostimulator; current use of any other investigational device or drug. * medical or mental instability (diagnosis of personality disorder, psychosis, or substance abuse) that would prevent the subject from following the protocol timeline. * pregnancy or planning to become pregnant or breastfeed during the study period. * botox injections or hemiplegia rehabilitation within 6 months before treatment. * having a history of hemorrhagic stroke * presence of ongoing dysphagia or aspiration difficulties.
palliation of dyspnea with mouth piece ventilation

Conditions: Dyspnea

Summary: an uncontrolled feasibility study on using mouth piece ventilation in palliation of dyspnea in subjects with incurable advanced disease. subjects are recruited from a local hospice and from oncology ward. the main outcomes are the compliance of the subjects with the treatment and alleviation of dyspnea during the treatment period.


Eligibility criteria:
inclusion criteria: * at least moderate dyspnea (nrs = numeric rating scale ≥ 4) * incurable advanced disease * able to understand the study and to give informed consent * would not gain from intensive care or resuscitation according to the treating physician exclusion criteria: * unable to participate and use mpv due to e.g. delirium or lack of co-operation * the cause of the dyspnea can be succesfully treated * unable to give informed consent
physiological response to exercise: sensor evaluation at specified exertions

Conditions: Heart Failure

Summary: assessment of sensor parameter in patients with heart failure.

evaluate the correlation of specific sensor parameters with clinical reference measurements in patients with heart failure.

Eligibility criteria:
inclusion criteria: * cognis crt-d model n119 or n120, functional bipolar leads: ra, rv, and lv lead all implanted for a minimum of 30 days * prescribed to optimal pharmacologic therapy for heart failure for at least 30 days prior to enrollment * age 18 or above, or of legal age to give informed consent specific to state and national law exclusion criteria: * documented hf decompensation, as defined by a hospitalization or greater than a doubling of baseline diuretic dose due to worsening hf, within the last 3 months * patients who are pacemaker dependent * creatinine ≥ 2.5 mg/dl test within the last 3 months * requires assistance walking, for example a cane or walker * have an atrial tachyarrhythmia that is permanent or persistent * have moderate to severe chronic pulmonary disease as defined by fev1 \< 55% predicted * documented life expectancy of less than 6 months * patients at an unreasonable risk of not being able to reach the investigational center in case of an emergency, per physician discretion * enrolled in any concurrent study
contain covid-19: convalescent plasma to limit covid-19 complications in hospitalized patients

Conditions: COVID-19; Coronavirus; Coronavirus Infection

Summary: this is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-sars-cov-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.

a total of 300 eligible subjects will be randomized in a 1:1 ratio to receive either convalescent plasma (cp) from people who have recovered from covid-19 containing antibodies to sars-cov-2 or a placebo control, lactated ringer's solution (lr) or saline solution (ss). hospitalized covid-19 patients aged ≥18 years of age with respiratory symptoms within 3 to 7 days from the onset of illness or within 3 days of hospitalization will be eligible to participate.

Eligibility criteria:
inclusion criteria 1. patients ≥18 years of age 2. hospitalized with laboratory confirmed covid-19 3. one or more of the following respiratory signs or symptoms: cough, chest pain, shortness of breath, fever, oxygen saturation ≤ 94%, abnormal cxr/ct imaging) 4. hospitalized for ≤ 72 hours or within day 3 to 7 days from first signs of illness 5. on supplemental oxygen, non-invasive ventilation or high-flow oxygen 6. patients may be on other randomized controlled trials of pharmaceuticals for covid -19 and patients who meet eligibility criteria will not be excluded on this basis. exclusion criteria 1. receipt of pooled immunoglobulin in past 30 days 2. contraindication to transfusion or history of prior reactions to transfusion blood products 3. invasive mechanical ventilation or extracorporeal membrane oxygenation (ecmo) 4. volume overload secondary to congestive heart failure or renal failure 5. unlikely to survive past 72 hours from screening based on the assessment of the investigator 6. unlikely to be able to assess and follow outcome due to poor functional status